Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 6, 2016

View Archived Issues

Concomitant pan-Raf/PI3K inhibition as promising new therapeutic strategy in multiple myeloma

Hsa-miR-623 suppresses lung adenocarcinoma cell proliferation and invasion

miR-558 and Smad4 as novel therapeutic targets for gastric cancer

Ang-Tie-2 interventions as potential adjunctive therapeutics for severe malaria

Sumitomo Dainippon Pharma develops PDE1 inhibitors

Wuhan LL Science and Technology Development announces nitric oxid donors

Sarepta licenses European rights to Summit's utrophin modulator pipeline for DMD

Gene therapy as a promising new approach for treating cystic fibrosis lung disease

Tenax Therapeutics provides clinical update for levosimendan

Achilles Therapeutics launched to develop immunotherapies for cancer

Redhill Biopharma commences phase II study of Yeliva in HCC

Insmed and AstraZeneca enter worldwide license agreement

Triphase Accelerator obtains rights to ADC from Catalent Biologics

Mitsubishi Tanabe and Daiichi Sankyo announce progress in malaria research programs with MMV

Gilead initiates phase II trial of GS-9876 in patients with active rheumatoid arthritis

MD Anderson initiates first-in-human study of IACS-010759 in relapsed or refractory AML

New company Kymo Therapeutics formed to advance KMO inhibitors

DTX-401 named FDA orphan drug for treating glycogen storage disease type Ia

Scynexis reports full results from phase II studies of antifungal SCY-078

Alnylam Pharmaceuticals discontinues development of revusiran

Cepheid launching Xpert Bladder Cancer Monitor in Europe

Immunomic Therapeutics and Nature Technology Corporation announce new license agreement

FDA warns on risk of HBV reactivation in patients taking direct-acting antivirals for HCV

Helmholtz-Zentrum fur Infektionsforschung develops lecB inhibitors

Toray Industries prepares and tests agents for urinary incontinence

Almirall patents Nav1.7 channel blockers for pain

Novira Therapeutics describes agents for HBV infection

Exosome Diagnostics and Amgen partner on liquid biopsy diagnostics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...